Latest news from the CGRP Forum
Aimovig (erenumab) receives EU approval for migraine prevention
Aimovig (erenumab) has received EU approval for the prevention of migraine in adults experiencing four or more migraine days per month.
Read the full report here »
CGRP infusion provokes cluster headache
CGRP infusion has been shown to provoke cluster headache attacks in active-phase episodic cluster headache and in chronic cluster headache, but not in remission-phase episodic headache.
Read the full report here »
Phase 3 EVOLVE-2 study of galcanezumab published in Cephalgia
Published data from the Phase 3 EVOLVE-2 study (NCT02614196) have confirmed that monthly treatment with galcanezumab 120 mg and 240 mg reduced mean monthly migraine headache days.
Read the full report here »
Recurrent headache + asthma + allergic rhinitis may = migraine in adolescents
Clinicians should be on the look-out for adolescents presenting with recurrent headache who also have asthma and allergic rhinitis as the combination is highly suggestive of migraine.
Read the full report here »
| Becoming a member is easy
Members have free open access simply by registering online. | |